Early stage squamous cell cancer of the oral tongue-clinicopathologic features affecting outcome

Abstract Objective To evaluate the outcome following the strategy of endoscopic R0 resection (ER) plus adjuvant treatment (AT) versus esophagectomy for esophageal squamous cell cancer in T1a invading muscularis mucosa (M3)-T1b stage. Methods We evaluated the outcomes of 46 esophageal squamous cell cancer (ESCC) patients with T1aM3-T1b stage who underwent ER + AT from the Esophageal Cancer Endoscopic Therapy Consortium (ECETC) and compared these outcomes to 92 patients who underwent esophagectomy. Propensity score matching (1:2) was used, with overall survival (OS) and relapse-free survival (RFS) being compared between the two groups. Results During a median follow-up of 32 months, there were no statistical differences (P = 0.226) in OS between the two groups. The 1-, 2-, and 3-year overall survival in the esophagectomy group was 95%, 91%, and 84%, respectively. There were no mortalities within three years in the ER + AT group. The RFS between the two groups was also not significantly different (P = 0.938). The 1-, 2-, and 3-year RFS of patients in the esophagectomy group was 90%, 90%, and 83%, respectively, while it was 97%, 94%, and 74% in the ER + AT group, respectively. The local recurrence rates between the two groups were not significantly different (P = 0.277). Conclusions This first multicenter analysis showed similar outcomes were found regarding OS and RFS between the two groups in T1aM3-T1b stage patients. ER + AT may be considered in high-risk patients or for those who refuse esophagectomy.

Download Full-text

Use of Ho:Yag laser in early stage oropharyngeal squamous cell cancer

World Journal of Otorhinolaryngology ◽

10.5319/wjo.v6.i2.41 ◽

2016 ◽

Vol 6 (2) ◽

pp. 41

Author(s):

Jagdeep S Virk ◽

Mike Dilkes

Keyword(s):

Squamous Cell ◽

Squamous Cell Cancer ◽

Early Stage ◽

Cell Cancer ◽

Ho:Yag Laser

Download Full-text

Prognosis of Patients less than 40 Years of Age with Squamous Cell Cancer of the Oral Tongue

International Journal of Head and Neck Surgery ◽

10.5005/jp-journals-10001-1222 ◽

2015 ◽

Vol 6 (2) ◽

pp. 53-56 ◽

Cited By ~ 1

Author(s):

Khalid Al-Qahtani ◽

Tahera Islam ◽

Valérie Brousseau

Keyword(s):

Prognostic Factor ◽

Squamous Cell ◽

Squamous Cell Cancer ◽

Tongue Cancer ◽

Cell Cancer ◽

Significant Prognostic Factor ◽

Tumor Differentiation ◽

Oral Tongue ◽

Significant Difference ◽

Oral Tongue Cancer

ABSTRACT Introduction Controversy exists about the prognosis of squamous cell carcinoma of the tongue between young and older patients. Our objective was to evaluate age as a prognostic factor in oral tongue cancer. Materials and methods A retrospective study was conducted by reviewing charts of 61 patients. They were divided into two age groups, below 40 years and above 40 years. Data regarding epidemiology pathology report, tumor differentiation, staging, treatment and outcome were obtained. The length of survival and disease recurrence was calculated and compared in this two age group. Statistical analysis was performed using student, t-test. Results The result showed no significant difference in prognosis, tumor differentiation or staging related to age in oral tongue cancer. Conclusion Although age is not a significant prognostic factor in oral tongue cancer, the disease etiology is likely different, we recommend prompt and aggressive treatment of young patients. How to cite this article Al-Qahtani K, Brousseau V, Islam T. prognosis of patients less than 40 Years of Age with Squamous Cell Cancer of the Oral Tongue. Int J Head Neck Surg 2015;6(2): 53-56.

Download Full-text

15 Squamous Cell Cancer of the Oral TongueTongue (oral tongue)cancer ofSquamous cell carcinomastongue

Oral Cancer ◽

10.1055/b-0040-176901 ◽

2020 ◽

Keyword(s):

Squamous Cell ◽

Squamous Cell Cancer ◽

Tongue Cancer ◽

Cell Cancer ◽

Oral Tongue ◽

Oral Tongue Cancer

Download Full-text

Current Standards and New Trends in Oesophageal Cancer

European Oncology & Haematology ◽

10.17925/eoh.2012.08.02.105 ◽

2012 ◽

Vol 08 (02) ◽

pp. 105

Author(s):

Florian Lordick ◽

Keyword(s):

Squamous Cell ◽

Squamous Cell Cancer ◽

Early Stage ◽

Symptom Control ◽

Cell Cancer ◽

Locally Advanced ◽

Standard Of Care ◽

Oesophageal Adenocarcinoma ◽

Term Survival ◽

Oesophagogastric Junction

Oesophageal squamous cell cancer has a constant or even decreasing incidence rate in many regions in Europe, while oesophageal adenocarcinoma and oesophagogastric junction (OGJ) cancer have shown an increasing incidence over the past three decades. If diagnosed at an early stage (stage I), which is rarely the case, these cancers have a good prognosis. Endoscopic resection can then be recommended in selected cases where the submucosal layer is not reached. In these cases, surgical resection is regarded as the standard of care. In contrast, in stages II and III, the prognosis is more critical. Local relapses and distant metastases occur frequently during post-surgical follow-up, leading to long-term survival being as poor as 2030 %. For locally advanced tumours, multimodal treatment has been established as the new standard of care. Neoadjuvant chemotherapy or chemoradiation have proven efficacy in adenocarcinoma of the oesophagus. Neoadjuvant chemoradiation (followed by surgery) and definitive chemoradiation are two proven and equivalent options with comparable outcomes in oesophageal squamous cell cancer. In metastatic disease, chemotherapy on the basis of cisplatin and 5-fluorouracil can be offered in order to achieve better symptom control, although prolongation of survival has not formally been proven due to a lack of randomised controlled clinical studies.

Download Full-text